Send us a text

Eli Mohamad is a prominent figure in the biotech, space, and AI industries who has co-founded several successful startups and has a real passion for groundbreaking ventures that focus on the development of futuristic technologies.

Currently as a Core Team Member at CryoDAO ( https://www.cryodao.org/ ), a decentralized organization focused on sourcing and funding research in cryopreservation, Eli continues to work at the forefront of innovative technologies and applies his extensive experience in biotechnology and innovative projects to advance novel cryopreservation technologies and their various applications, from critical tissue and organ preservation, to cryo-sleep and suspended animation for space exploration.

Eli has also been involved in setting up another decentralized organization called HydraDAO ( https://hydradao.org/ ) which is focused on funding and incubating biological replacement research to significantly extend human lifespan and will be looking at everything from Limb Regeneration, Organ Bioprinting and Xenotransplantation, to  Progressive Brain Replacement,  head/brain transplants, and even whole body replacement via non sentient cloning.

Throughout his career, Eli has held various leadership positions in cutting-edge companies including as Co-founder and Chief Business Officer at X-Therma Inc., a company focused on complex tissue preservation; Advisor and Chief Business Officer at Rimac Automobili, working on high-performance electric vehicles; CFO/CBO at Insilico Medicine, Inc., as well as Co-founder of Organ Preservation Alliance, a non-profit organization dedicated to the future of organ banking, Orphidia Ltd., a medical diagnostics company, and Walkmore, a data science company.

Eli holds a Master's degree in Science, Technology and Innovation Management from the University of Sussex. He is also an alumnus of Singularity University's GSP (Global start up) 2012 program.  

Kai Micah Mills ( https://kaimicahmills.com/ ) is the visionary founder of Cryopets ( https://cryopets.com/ ), a company focused on advancing cryopreservation technologies for pets. Cryopets was founded in 2023 with the aim of revolutionizing the field of cryopreservation. Starting with pets, the company is innovating on existing methods to create reliable and accessible cryopreservation services. Cryopets aspires to make cryopreservation available in local veterinary clinics and, eventually, in human hospitals.

With a deep passion for defeating death, Kai is driven by the belief that true progress in longevity science must be bold and unapologetic. He has received backing from the prestigious Thiel Fellowship and is a recognized thought leader in the radical life extension community.

Kai is a co-founder of CryoDAO and HydraDao.

Important Episode Link - Vitalist Bay - https://www.vitalistbay.com/

#EliMohamad #KaiMicahMills #Longevity #Immortality #LifeExtension #ProgressiveBrainReplacement #Cryopreservation #OrganPreservation #Bioprinting #VitalistBay #Vitalism #AdamGries #NathanCheng #HydraDAO #CryoDAO #DeSci #Cryonics #Regeneration #Cryoprotectants #LimbRegeneration #Xenotransplantation #HeadTransplant #BrainTransplant #SpinalCordInjury #SergioCanavero #RenXiaoping #ClonedNonSentientBodies #Cloning #ArtificialWombs #Cryosleep #Crypto #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research

Support the show

Send us a text

Dr. Nahid Bhadelia, MD, MALD is a board-certified infectious diseases physician who is the Founding Director of BU Center on Emerging Infectious Diseases ( https://www.bu.edu/ceid/about-the-center/team/nahid-bhadelia-md-mald/ ) as well an Associate Professor at the BU School of Medicine. She served the Senior Policy Advisor for Global COVID-19 Response for the White House COVID-19 Response Team in 2022-2023, where she coordinated the interagency programs for global COVID-19 vaccine donations from the United States and was the policy lead for Project NextGen, $5B HHS program aimed at developing next generation vaccines and treatments for pandemic prone coronaviruses. She also served as the interim Testing Coordinator for the White House MPOX Response Team. She is the Director and co-founder of Biothreats Emergence, Analysis and Communications Network (BEACON), an open source outbreak surveillance program. 

Between 2011-2021, Dr. Bhadelia helped develop and then served as the medical director of the Special Pathogens Unit (SPU) at Boston Medical Center, a medical unit designed to care for patients with highly communicable diseases, and a state designated Ebola Treatment Center. She was previously an associate director for BU’s maximum containment research program, the National Emerging Infectious Diseases Laboratories. She has provided direct patient care and been part of outbreak response and medical countermeasures research during multiple Ebola virus disease outbreaks in West and East Africa between 2014-2019. She was the clinical lead for a DoD-funded viral hemorrhagic fever clinical research unit in Uganda, entitled Joint Mobile Emerging Disease Intervention Clinical Capability (JMEDICC) program between 2017 and 2022. Currently, she is a co-director of Fogarty funded, BU-University of Liberia Emerging and Epidemic Viruses Research training program. She was a member of the World Health Organization(WHO)’s Technical Advisory Group on Universal Health and Preparedness Review (UHPR).  She currently serves as a member of the National Academies Forum on Microbial Threats and previously served as the chair of the National Academies Workshop Committee for Potential Research Priorities to Inform Readiness and Response to Highly Pathogenic Avian Influenza A (H5N1) and member of the Ad Hoc Committee on Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures.

Dr. Bhadelia’s research focuses on operational global health security and pandemic preparedness, including medical countermeasure evaluation and clinical care for emerging infections, diagnostics evaluation and positioning, infection control policy development, and healthcare worker training. She has health system response experience with pathogens such as H1N1, Zika, Lassa fever, Marburg virus disease, and COVID-19 at the state, national, and global levels. 

#NahidBhadelia #BostonUniversity #CenterOnEmergingInfectiousDiseases #HIV #EmergingInfections #Policy #Preparedness #HealthSecurity #SpecialPathogensUnit #BSL4 #Ebola #HotZones #DataScience #DiseaseSurveillance #OneHealth #H1N1 #Zika #LassaFever #MarburgVirus #Covid #InfectiousDiseases #Outbreaks #Zoonoses #Epidemics #Pandemics #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research

Support the show

Send us a text

Dr. Debra Whitman, Ph.D. is Executive Vice President and Chief Public Policy Officer, at AARP ( https://www.aarp.org/ ) where she leads policy development, analysis and research, as well as global thought leadership supporting and advancing the interests of individuals age 50-plus and their families. She oversees AARP’s Public Policy Institute, AARP Research, Office of Policy Development and Integration, Thought Leadership, and AARP International.

Dr. Whitman is an authority on aging issues with extensive experience in national policy making, domestic and international research, and the political process. An economist, she is a strategic thinker whose career has been dedicated to solving problems affecting economic and health security, and other issues related to population aging.

As staff director for the U.S. Senate Special Committee on Aging, Dr. Whitman worked across the aisle to increase retirement security, lower the cost of health care, protect vulnerable seniors, safeguard consumers, make the pharmaceutical industry more transparent, and improve our nation’s long term care system.

Before that, Dr. Whitman worked for the Congressional Research Service as a specialist in the economics of aging. She provided members of Congress and their staff with research and advice, and authored analytical reports on the economic impacts of current policies affecting older Americans, as well as the distributional and intergenerational effects of legislative proposals.

From 2001 to 2003, Dr. Whitman served as a Brookings LEGIS Fellow to the U.S. Senate Committee on Health, Education, Labor and Pensions. Earlier in her career, she conducted research on savings and retirement for the Social Security Administration, helping to establish the Retirement Research Consortium and serving as the founding editor of the Perspectives section of the Social Security Bulletin.

Dr. Whitman has been quoted by or appeared in numerous media outlets including The New York Times, Bloomberg, USA Today, NBC Nightly News, CBS News, The Huffington Post, The Washington Post, and Politico, among others. She serves on several boards, including the National Advisory Council on Aging for the National Institutes of Health’s National Institute on Aging, the Columbia University Mailman School of Public Health, the National Coalition on Health Care, and the Pension Rights Center.

Dr. Whitman holds master’s and doctorate degrees in economics from Syracuse University and a bachelor’s degree in economics, math and Italian from Gonzaga University.

Dr. Whitman recently released 𝘛𝘩𝘦 𝘚𝘦𝘤𝘰𝘯𝘥 𝘍𝘪𝘧𝘵𝘺: 𝘈𝘯𝘴𝘸𝘦𝘳𝘴 𝘵𝘰 𝘵𝘩𝘦 7 𝘉𝘪𝘨 𝘘𝘶𝘦𝘴𝘵𝘪𝘰𝘯𝘴 𝘰𝘧 𝘔𝘪𝘥𝘭𝘪𝘧𝘦 𝘢𝘯𝘥 𝘉𝘦𝘺𝘰𝘯𝘥 ( https://www.amazon.com/Second-Fifty-Answers-Questions-Midlife/dp/039386765X ), to explore the most important questions we face as we age and offer practical advice for living a longer, healthier, more meaningful second half of life.

#AARP #Aging #AmericanAssociationOfRetiredPersons #DebraWhitman #AgeTech #Longevity #Geroscience #Gerontology #Dementia #Alzheimers #LifeLongLearning #PalliativeCare #Hospice #EndOfLife #Death #Dying #USSenateSpecialCommitteeOnAging #Economics #SocialSecurity #Medicare #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #Research

Support the show

Send us a text

Dr. Marcia McNutt, Ph.D. is President of the National Academy of Sciences ( https://www.nasonline.org/directory-entry/marcia-mcnutt-6apamq/ ), where she also chairs the National Research Council, the operating arm of the National Academies of Sciences, Engineering, and Medicine, and serves a key role in advising our nation on various important issues pertaining to science, technology, and health.

From 2013 to 2016, Dr. McNutt served as editor-in-chief of the Science journals. 

Dr. McNutt is a geophysicist who prior to joining Science, was director of the U.S. Geological Survey (USGS) and science adviser to the United States Secretary of the Interior from from 2009 to 2013. During her tenure, the USGS responded to a number of major disasters, including earthquakes in Haiti, Chile, and Japan, and the Deepwater Horizon oil spill. 

Dr. McNutt led a team of government scientists and engineers at BP headquarters in Houston who helped contain the oil and cap the well. She directed the flow rate technical group that estimated the rate of oil discharge during the spill’s active phase. For her contributions, she was awarded the U.S. Coast Guard’s Meritorious Service Medal.

Before joining the USGS, Dr. McNutt served as president and chief executive officer of the Monterey Bay Aquarium Research Institute (MBARI), in Moss Landing, California. During her time at MBARI, the institution became a leader in developing biological and chemical sensors for remote ocean deployment, installed the first deep-sea cabled observatory in U.S. waters, and advanced the integration of artificial intelligence into autonomous underwater vehicles for complex undersea missions.

From 2000 to 2002, Dr. McNutt served as president of the American Geophysical Union (AGU). She was chair of the Board of Governors for Joint Oceanographic Institutions, responsible for operating the International Ocean Drilling Program’s vessel JOIDES Resolution and associated research programs.

Dr. McNutt is a National Association of Underwater Instructors (NAUI)-certified scuba diver and trained in underwater demolition and explosives handling with the Underwater Demolition Team (UDT) of the United States Navy and the United States Navy SEALs.

Dr. McNutt began her academic career at the Massachusetts Institute of Technology (MIT), where she was the E.A. Griswold Professor of Geophysics and directed the Joint Program in Oceanography/Applied Ocean Science & Engineering, jointly offered by MIT and the Woods Hole Oceanographic Institution. Her research area is the dynamics of the upper mantle and lithosphere on geologic time scales, work that has taken her to distant continents and oceans for field observations. She is a veteran of more than a dozen deep-sea expeditions, on most of which she was chief or co-chief scientist.

Dr. McNutt received a B.A. in physics from Colorado College and her Ph.D. in Earth sciences at the Scripps Institution of Oceanography. She holds honorary doctoral degrees from the Colorado College, the University of Minnesota, Monmouth University, the Colorado School of Mines, University of Miami, Uppsala University, Michigan State University, Worcester Polytechnic Institute, George Washington University, Boston University, Texas A&M University, Indiana University Bloomington, and the National Academy of Sciences of Ukraine. 

#MarciaMcNutt #NationalAcademyOfSciences #Convergence #USGeologicalSurvey #ScienceMagazine #MontereyBayAquariumResearchInstitute #AmericanGeophysicalUnion #MIT #Geoscience #EarthScience #Physics #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast

Support the show

Send us a text

Dr. Nina Siragusa, Ph.D., MBA, is the Strategy, Business, and Data & Digital Lead within the global R&D organization of Merck Healthcare KGaA, Darmstadt, Germany. In this role, she leads strategic projects, manages business operations, and drives digital transformation.

Previously, she served as Chief of Staff to Dr. Laura Matz, Chief Science and Technology Officer at Merck KGaA, Darmstadt, Germany. As part of the Science and Technology Office Leadership Team, she was responsible for fostering cross-sectoral collaboration, innovation, and digitalization across Merck’s three business sectors. She also spearheaded the company’s efforts in Bioconvergence, a multidisciplinary approach that synergizes biology, engineering, data, and digitalization. This initiative promises groundbreaking advancements in healthcare and the life sciences, heralding a new era of scientific collaboration for a healthier, more sustainable future.

Prior to that, Dr. Siragusa contributed to corporate innovation in several leadership roles:

• As Biotechnology Lead of a synthetic biology innovation project,
• As Senior Manager, responsible for creating strategic alignment and building high-performing teams, and
• As Associate Director, focusing on sourcing innovative ideas to generate new business opportunities.

Dr. Siragusa earned her Ph.D. in Biology from the University of Tuebingen, Germany, and conducted research in Europe and the USA, including at Yale University, before joining Merck KGaA, Darmstadt, Germany in 2016.

In 2024, she completed an MBA in Digital Transformation Management with a focus on Digital Leadership at Goethe Business School, Frankfurt, Germany.

Dr. Siragusa is also the lead author of the recently published book, Bioconvergence Revolution: Challenges and Opportunities in Research Productivity. You can find it here: 

https://link.springer.com/book/10.1007/978-3-031-61593-1

Home Page Merck KGaA Darmstadt, Germany - https://www.emdgroup.com/en

#NinaSiragusa #EMDGroup #MerckKGaADarmstadtGermany #Bioconvergence #Ethics #Collaboration #Fungi #NaturalProducts #Biomimicry #AI #DrugDiscovery #Bioremediation #TranslationalMedicine #SmartManufacturing #DigitalTwins #Supermind #MIT #ResearchFunding #Israel #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast

Support the show

Send us a text

Dr. Jackie Kunzler, Ph.D. is Senior Vice President and Global Head of Research and Development (R&D), and member of the Executive Management Committee, of Terumo Blood and Cell Technologies ( https://www.terumobct.com/ ), where she focuses on innovation and development leading the way for unlocking the potential of blood and cell collections in varied sectors, including blood banking, plasma-based therapies and cell and gene therapies.

Dr. Kunzler joined Terumo from Baxter Healthcare where she held successive leadership roles in their business, including as Baxter Healthcare's Senior Vice President for Quality and Regulatory and Head of Global Life Sciences.

Dr. Kunzler holds a Ph.D. in Cell Biology/Neuroscience from the University of Illinois, Chicago. She earned a Master of Science in Toxicology from the University of Florida, Bachelor’s degrees in Biology and Medical Technology (Laboratory Medicine) from University of Iowa and an MBA in Healthcare Administration from Benedictine University.

#Terumo #JackieKunzler #Blood #SickleCell #Alzheimers #Dementia #Biotherapies #Immunology #TherapeuticApheresis #AutoimmuneDiseases  #BloodDisorders  #BloodBanking #TransfusionMedicine #RegenerativeMedicine #TherapeuticPlasmaExchange #ConvalescentPlasma #ExtracorporealPhotopheresis #Parabiosis #Longevity #Aging #HospiceCare #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast

Support the show

Send us a text

Sam Murray, MT-BC, CADDCT, CDP, is a Music Therapist at Goodwin Living ( https://goodwinliving.org/ ), a non-profit senior living and healthcare organization, located in Northern Virginia, that serves more than 2,500 older adults in the National Capital Region (Northern Virginia, Washington, DC, and Maryland) and more than 25,000 older adults across the nation who participate in their brain health programs.

Sam and her team are exploring novel ways to help residents living with mild cognitive impairment or dementia connect with through music therapy programs. With approximately 7 million Americans facing Alzheimer's today, and the eventual loss of communication that they experience, music therapy is becoming more widely acknowledged by many experts as a viable way to communicate with individuals for whom language is no longer enough, helping to re-establish comfort and connection.

Goodwin Living’s foundation recently invested in a new instrument called the Crdl ( https://www.crdl.com/ ) that helps translate physical touch into music, in essence transforming a person's body into an instrument, for an entirely new concept in communications and human interaction. 

#GoodwinLiving #SamMurray #SamTedrow #SeniorLiving #Crdl #MusicTherapy #BrainHealth #Neurodivergent #Dementia #Alzheimers #SocialIsolation #PallaitiveCare #Hospice #EndOfLifeCare #Autism #MentalDisabilities #VisualImpairments #FrancisCollins #ReneeFleming  #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast

Support the show

Send us a text

Dr. David Feinberg, M.D., is Chairman of Oracle Health ( https://www.oracle.com/health/ ), where he and his team are committed to making healthcare more accessible, affordable and equitable, building an open healthcare platform with intelligent tools for data-driven, human-centric healthcare experiences to connect consumers, healthcare providers, payers, and public health and life sciences organizations.

Dr. Feinberg’s work advances thought leadership and strategy related to unleashing the healing power of data through an open and connected healthcare ecosystem. 

Previously, Dr. Feinberg served as president and CEO of Cerner, now Oracle Health, where he led teams delivering tools and technology to execute on this strategy of improving the patient and caregiver experience. 

As a pediatric psychiatrist, Dr. Feinberg built his early career around helping children and families. He served as president and CEO of both UCLA Health and Geisinger Health prior to assuming leadership of Google Health in early 2019. 

Dr. Feinberg began his career at UCLA, researching and publishing in the areas of addiction and attention deficit hyperactivity disorder. He took on additional leadership responsibilities, including becoming the Medical Director of the Resnick Neuropsychiatric Hospital. 

Dr. Feinberg earned his M.D. from Chicago Medical School in 1989, finishing at the top of his class and is a member of the Alpha Omega Alpha Medical Honor Society. He also holds an economics degree from the University of California-Berkeley and an MBA from Pepperdine University.

#DavidFeinberg #OracleHealth #Oracle #LarryEllison #GoogleHealth #GeisingerHealth #UCLAHealth #ElectronicHealthRecords #EHR #ClinicalDigitalAssistant #PediatricPsychiatry #SocialDeterminantsOfHealth #ArtificalIntelligence #MentalHealth #AgingInPlace #DigitalHealth #FoodPharmacy #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research

Support the show

Send us a text

Robert Stone is the CEO of City of Hope ( https://www.cityofhope.org/robert-stone ), a premier cancer research and treatment center dedicated to innovation in biomedical science and the delivery of compassionate, world-class patient care. A seasoned health care executive, he has served in a number of strategic decision-making roles since he joined City of Hope in 1996, culminating with his appointment as president in 2012, CEO in 2014, and as the Helen and Morgan Chu Chief Executive Officer Distinguished Chair in 2021.

Mr. Stone has J.D., University of Chicago Law School, Chicago, IL.

Mr. Stone’s strategic acumen, empathy and visionary leadership have driven City of Hope’s rapid evolution. 

As an independent institution dedicated to advancing the fight against cancer and diabetes, City of Hope is accelerating opportunities for high-impact discovery and ensuring that patients around the world have access to the most advanced therapies. Recent examples include a groundbreaking alliance in precision medicine with the Translational Genomics Research Institute (TGen), a leader in genomic analysis and bioinformatics; leadership in CAR T cell therapy research and therapy; and an innovative program to offer cancer support services to the employees of some of American’s largest employers, regardless of geography.


Dr. Marcel van den Brink, M.D., Ph.D.( https://www.cityofhope.org/marcel-van-den-brink ), is President of City of Hope Cancer Center, main campus in Los Angeles, and National Medical Center, chief physician executive and the Deana and Steve Campbell Chief Physician Executive Distinguished Chair, and is a globally recognized leader in the basic and translational science of bone marrow transplantation (BMT), the microbiome and cancer immunotherapy.  His specialties include immune reconstitution and graft-versus-host disease — side effects many BMT patients experience — as well as the impact of the microbiome on immunotherapy for cancer. 

A researcher who has opened new fields of investigation and improved patient outcomes, Dr. Van den Brink has pursued innovative ways to improve and optimize BMT, developing strategies to make the process less toxic and lower the rate of recurrence. Throughout his career, he has maintained an intense focus on converting scientific discoveries in his laboratory into better therapies for patients around the world.

Dr. Van den Brink joined City of Hope in part because of their shared commitment to advancing the frontiers of cancer care and research. He is known for his inclusive approach to leadership and his devotion to providing junior faculty colleagues with mentorship and career development opportunities.

A recipient of numerous national and international awards, Dr. Van den Brink is a member of the Royal Netherlands Academy of Arts and Sciences. Among many leadership roles, he serves as vice chair of the board for Deutsche Knochenmark Stiftung, a global donor registration that facilitates 40% of all unrelated allogenic blood stem cell donations worldwide.


Dr. Van den Brink has a Ph.D., Medicine (Immunology), and M.D., Cum Laude, University of Leiden, The Netherlands, completed a postdoctoral fellowship at the Pittsburgh Cancer Institute in Pittsburgh, PA and residency at Duke University Medical Center in Durham, NC. 


#Cancer #Oncology #CityOfHope #RobertStone #MarcelVanDenBrink #Microbiome #Immunotherapy #CarT #Thymus #ThymicInvolution #Regeneration #BoneMarrowTransplantation #TranslationalGenomicsResearchInstitute #PrecisionMedicine #GraftVersusHostDisease #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research

Support the show

Send us a text

Dr. Sudip Parikh, Ph.D. ( https://www.aaas.org/person/sudip-parikh ), is the Chief Executive Officer of the American Association for the Advancement of Science (AAAS) and Executive Publisher of the Science family of journals and has spent the last two decades at the nexus of science, policy, and business.

Prior to joining AAAS, Dr. Parikh was senior vice president and managing director at Drug Information Association (DIA Global), a neutral, multidisciplinary organization for healthcare product development where he led strategy in the Americas and oversaw DIA programs that catalyzed progress globally toward novel regulatory frameworks for advanced therapies.

Prior to DIA, Dr. Parikh was a vice president at Battelle, a multibillion-dollar research and development organization, where he led two business units with over 500 scientific, technical, and computing experts performing basic and applied research, developing medicines and healthcare devices, developing agricultural products, and creating advanced analytics and artificial intelligence applications to improve human health.

From 2001 to 2009, Dr. Parikh served as science advisor to the Republican leadership of the U.S. Senate Appropriations Committee, where he was responsible for negotiating budgets for the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Agency for Healthcare Research and Quality, Biomedical Advanced Research and Development Authority (BARDA), and other scientific and health agencies.

As a key legislative liaison to the research and development ecosystem, Dr. Parikh was on the frontlines of many science policy issues debated during that time, including embryonic stem cell research, cloning, disease surveillance, bioterrorism, cyber security, and doubling the NIH budget.

An active member of the scientific advocacy community, Dr. Parikh serves as a board member and officer for several impactful organizations, including Research!America ( https://www.researchamerica.org/ ), which he has chaired since 2023, Friends of Cancer Research, and ACT for NIH.  He also serves as co-chair of the Science and Technology Action Committee ( https://sciencetechaction.org/ ), Science CEO Group, and the Coalition for Trust in Health and Science ( https://trustinhealthandscience.org/ ).  He is also a member of the Board of Life Sciences of the U.S. National Academies of Science, Engineering, and Medicine.

Dr. Parikh is an elected member of the American Academy of Arts and Sciences and the Council on Foreign Relations. He has also received multiple public service awards, including recognition from the Society for Women’s Health Research, the American Association of Immunologists, the National AIDS Alliance, the Coalition for Health Services Research, and the Juvenile Diabetes Research Foundation.

Early in his career, Dr. Parikh was a Presidential Management Intern at the NIH. He was awarded a National Science Foundation Graduate Research Fellowship while earning his Ph.D. in macromolecular structure and chemistry at the Scripps Research Institute in La Jolla, Calif.  There, he used structural biology and biochemistry techniques to probe the mechanisms of DNA repair enzymes.  

Dr. Parikh completed undergraduate studies at the University of North Carolina at Chapel Hill, first as a journalism major before switching into materials science. 

#SudipParikh #AAAS #AmericanAssociationForTheAdvancementOfScience #Science #Policy #Business #DrugInformationAssociation #Battelle #ResearchAmerica  #ScienceAndTechnologyActionCommittee #CoalitionForTrustInHealthAndScience #Appropriations #Congress #ArtificialIntelligence #DrugDevelopment #ProgressPotentialAndPossibilit

Support the show